Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the ...

Guardant Health (NASDAQ:GH – Get Free Report) had its target price upped by Piper Sandler from $34.00 to $50.00 in a report ...

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

Guardant Health (NYSE:GH) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health (GH) to $50 from $34 following quarterly results. The ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Guardant Health (GH) one of those stocks right now? By taking ...

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Guardant Health (GH – Research Report), with a price ...

Guggenheim restated their buy rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Monday ...

The oncology testing specialist reported strong top-line growth, but also rising costs and ongoing net losses.

Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions ...

Guardant Health is a leader in liquid biopsy. It has market leading platforms in genomics profiling, molecular residual disease, or MRD, testing, and single cancer screening for colorectal cancer ...